Press Releases

Date Title and Summary View
Toggle Summary World-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin Therapeutics as Special Consultant to Accelerate and Enhance Development of Company’s Galectin-3 Inhibitor, Belapectin
Galectin Therapeutics also announces new $10 million convertible debt financing from its Chairman, Richard E. Uihlein NORCROSS, Ga., April 19, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it
View HTML
Toggle Summary Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy
Combination therapy with belapectin suggests a better objective response rate with fewer adverse events than pembrolizumab (KEYTRUDA®) alone NORCROSS, Ga., April 13, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin
View HTML
Toggle Summary Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis Study
Galectin Therapeutics is actively recruiting patients into NAVIGATE, its seamless, adaptive Phase 2b/3 study of belapectin for the prevention of esophageal varices in NASH cirrhosis NORCROSS, Ga., April 06, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.
View HTML
Toggle Summary Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update
NORCROSS, Ga., March 31, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2020.
View HTML
Toggle Summary OncoImmunology Publishes Pre-clinical Research Showing Galectin Therapeutics’ Belapectin Galectin-3 Inhibitor Reduces Tumor Progression in Combination with Anti-OX40 Therapy
Research deciphers belapectin’s mechanism of action, further rationalizing its use in combination with checkpoint inhibitors or T cell agonists in oncology and as a monotherapy in NASH cirrhosis NORCROSS, Ga., March 08, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.
View HTML
Toggle Summary Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
NORCROSS, Ga., March 04, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Pol Boudes, M.D., Chief Medical Officer, will provide a corporate overview at the upcoming H.C.
View HTML
Toggle Summary Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020
NORCROSS, Ga., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D., Chief Medical Officer, has been invited to make a presentation, entitled “Belapectin, a
View HTML
Toggle Summary Galectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders Presentation
Chairman Dick Uihlein, CEO and President Joel Lewis, and Chief Medical Officer Pol Boudes Provide Corporate Highlights on Company’s Three Active Clinical Trials NORCROSS, Ga., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that
View HTML
Toggle Summary Galectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of Stockholders
NORCROSS, Ga., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business portion of its 2020
View HTML
Toggle Summary Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020
Innovative Phase 2b/3 NASH-RX Trial in NASH Cirrhosis Initiated Board Member Joel Lewis Assumes CEO Role – Board Adds Two New Highly Accomplished Professionals NORCROSS, Ga., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that
View HTML